clinical trial · NCT07214779
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
Ovarian CancerINCB123667Investigator's choice of chemotherapy
brief summary
The purpose of this study is to evaluate INCB123667 versus investigator's choice of chemotherapy in participants with platinum-resistant ovarian cancer with cyclin E1 overexpression.
started
Dec 9, 2025
primary completion
Nov 15, 2028
completion
May 14, 2029
last updated
Apr 16, 2026
official title
A Phase 3, Randomized, Open-Label Study of INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol